{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:55:20Z","timestamp":1794282920635,"version":"4.9.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.vascn.2023.107270","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T21:08:11Z","timestamp":1683580091000},"page":"107270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14\/S7B Q&amp;As"],"prefix":"10.1016","volume":"123","author":[{"given":"Eric I.","family":"Rossman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Wisialowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo M.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Rolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Pugsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingzhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.","family":"Leishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Kleiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Greiter-Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Gintant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Engwall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Delaunois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Authier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2023.107270_bb0005","series-title":"ICH E14\/S7B Implementation Working Group: Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential Questions and Answers","author":"Anonymous","year":"2022"},{"key":"10.1016\/j.vascn.2023.107270_bb0010","series-title":"ICH E14\/S7B implementation working group: E14\/S7B questions and answers: Clinical and nonclinical evaluation of QT\/QTc interval prolongation and Proarrhythmic potential. Training Materials","author":"Anonymous","year":"2022"},{"issue":"2","key":"10.1016\/j.vascn.2023.107270_bb0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.vascn.2011.05.007","article-title":"Evaluation of a novel ECG lead placement method in telemetered freely moving cynomolgus monkeys: Assessment of an intravascular biopotential lead","volume":"64","author":"Authier","year":"2011","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"3","key":"10.1016\/j.vascn.2023.107270_bb0020","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/pst.454","article-title":"Review of the statistical analysis of the dog telemetry study","volume":"10","author":"Aylott","year":"2011","journal-title":"Pharmaceutical Statistics"},{"key":"10.1016\/j.vascn.2023.107270_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2021.107067","article-title":"The in vivo QTc core assay: An evaluation of QTc variability, detection sensitivity and implications for the improvement of conscious dog and non-human primate telemetry studies","volume":"109","author":"Baublits","year":"2021","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"6","key":"10.1016\/j.vascn.2023.107270_bb0030","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/1091581820954865","article-title":"Confounders and pharmacological characterization when using the QT, JTp, and Tpe intervals in beagle dogs","volume":"39","author":"Boulay","year":"2020","journal-title":"International Journal of Toxicology"},{"key":"10.1016\/j.vascn.2023.107270_bb0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/pst.30","article-title":"Modelling covariance structure in ascending dose studies of isolated tissues and organs","volume":"2","author":"Brammer","year":"2003","journal-title":"Pharmaceutical Statistics"},{"issue":"1","key":"10.1016\/j.vascn.2023.107270_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vascn.2014.05.004","article-title":"Translational PK\/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development","volume":"70","author":"Caruso","year":"2014","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2023.107270_bb0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.vascn.2007.04.002","article-title":"ILSI-HESI cardiovascular safety subcommittee dataset: An analysis of the statistical properties of QT interval and rate-corrected QT interval (QTc)","volume":"56","author":"Chiang","year":"2007","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"6","key":"10.1016\/j.vascn.2023.107270_bb0050","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/cts.13103","article-title":"Evaluation of moxifloxacin in canine and non-human primate telemetry assays: Comparison of QTc interval prolongation by timepoint and concentration-QTc analysis","volume":"14","author":"Chui","year":"2021","journal-title":"Clinical and Translational Science"},{"issue":"4","key":"10.1016\/j.vascn.2023.107270_bb0055","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.60","article-title":"Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase","volume":"97","author":"Darpo","year":"2015","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1016\/j.vascn.2023.107270_bb0060","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ahj.2014.06.003","article-title":"Cardiac safety research consortium: Can the thorough QT\/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward","volume":"168","author":"Darpo","year":"2014","journal-title":"American Heart Journal"},{"issue":"2","key":"10.1016\/j.vascn.2023.107270_bb0065","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bph.12484","article-title":"Detection of QTc interval prolongation using jacket telemetry in conscious non-human primates: Comparison with implanted telemetry","volume":"171","author":"Derakhchan","year":"2014","journal-title":"British Journal of Pharmacology"},{"issue":"3","key":"10.1016\/j.vascn.2023.107270_bb0070","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/cvr\/cvy305","article-title":"Hypothermia and cardiac electrophysiology: A systematic review of clinical and experimental data","volume":"115","author":"Dietrichs","year":"2019","journal-title":"Cardiovascular Research"},{"issue":"8","key":"10.1016\/j.vascn.2023.107270_bb0075","doi-asserted-by":"crossref","first-page":"8814","DOI":"10.1007\/s11356-020-07761-0","article-title":"Better define beta-optimizing MDD (minimum detectable difference) when interpreting treatment-related effects of pesticides in semi-field and field studies","volume":"27","author":"Duquesne","year":"2020","journal-title":"Environmental Science and Pollution Research International"},{"key":"10.1016\/j.vascn.2023.107270_bb0080","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.vascn.2016.04.008","article-title":"QT interval correction for drug-induced changes in body temperature during integrated cardiovascular safety assessment in regulatory toxicology studies in dogs: A case study","volume":"81","author":"El Amrani","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2023.107270_bb0085","article-title":"Evaluation of levocetirizine in beagle dog and cynomolgus monkey telemetry assays: Defining the no QTc effect profile by timepoint and concentration-QTc analysis","volume":"Nov11","author":"Engwall","year":"2022","journal-title":"Clinical and Translational Science"},{"key":"10.1016\/j.vascn.2023.107270_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2021.107126","article-title":"Improving corrected QT; why individual correction is not enough","volume":"113","author":"Ether","year":"2022","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2023.107270_bb0095","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/toxsci\/kfu198","article-title":"The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative","volume":"142","author":"Ewart","year":"2014","journal-title":"Toxicological Sciences"},{"issue":"12","key":"10.1016\/j.vascn.2023.107270_bb0100","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/jcph.347","article-title":"Concentration-effect modeling based on change from baseline to assess the prolonging effect of drugs on QTc together with an estimate of the circadian time course","volume":"54","author":"Ferber","year":"2014","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2023.107270_bb0105","series-title":"The Design of Experiments","author":"Fisher","year":"1935"},{"issue":"3","key":"10.1016\/j.vascn.2023.107270_bb0110","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0197-2456(85)90002-9","article-title":"Adjusting for baseline measurements in the two-period crossover study: A cautionary note","volume":"6","author":"Fleiss","year":"1985","journal-title":"Controlled Clinical Trials"},{"issue":"135","key":"10.1016\/j.vascn.2023.107270_bb0115","first-page":"36791","article-title":"International conference on harmonisation; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability","volume":"66","author":"Food, & Drug Administration, H. H. S","year":"2001","journal-title":"Federal Register"},{"issue":"202","key":"10.1016\/j.vascn.2023.107270_bb0120","first-page":"61134","article-title":"International conference on harmonisation; guidance on E14 clinical evaluation of QT\/QTc interval prolongation and Proarrhythmic potential for non-antiarrhythmic drugs; availability","volume":"70","author":"Food, & Drug Administration, H. H. S","year":"2005","journal-title":"Federal Register"},{"issue":"202","key":"10.1016\/j.vascn.2023.107270_bb0125","first-page":"61133","article-title":"International conference on harmonisation; guidance on S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals; availability","volume":"70","author":"Food, & Drug Administration, H. H. S","year":"2005","journal-title":"Federal Register"},{"issue":"3","key":"10.1016\/j.vascn.2023.107270_bb0130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10928-017-9565-6","article-title":"Correction to: Scientific white paper on concentration-QTc modeling","volume":"45","author":"Garnett","year":"2018","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"3","key":"10.1016\/j.vascn.2023.107270_bb0135","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","article-title":"Scientific white paper on concentration-QTc modeling","volume":"45","author":"Garnett","year":"2018","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"6","key":"10.1016\/j.vascn.2023.107270_bb0140","doi-asserted-by":"crossref","first-page":"14B","DOI":"10.1016\/0002-9149(93)90034-A","article-title":"How to measure the QT interval--what is normal?","volume":"72","author":"Garson","year":"1993","journal-title":"The American Journal of Cardiology"},{"issue":"3","key":"10.1016\/j.vascn.2023.107270_bb0145","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1177\/0962280217736541","article-title":"Robustness of crossover trials against subject drop-out - examples of perpetually connected designs","volume":"28","author":"Godolphin","year":"2019","journal-title":"Statistical Methods in Medical Research"},{"key":"10.1016\/j.vascn.2023.107270_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2014.12.008","article-title":"Sensitivity of pharmacokinetic-pharmacodynamic analysis for detecting small magnitudes of QTc prolongation in preclinical safety testing","volume":"72","author":"Gotta","year":"2015","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2023.107270_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2022.107167","article-title":"Nonclinical cardiovascular safety assessment of thioridazine: Impact of autonomic tone, body temperature, and choice of species","volume":"115","author":"Greiter-Wilke","year":"2022","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"3","key":"10.1016\/j.vascn.2023.107270_bb0160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vascn.2008.03.004","article-title":"How many ECG leads are required for in vivo studies in safety pharmacology?","volume":"57","author":"Hamlin","year":"2008","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2023.107270_bb0165","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.vascn.2010.05.017","article-title":"Left thoracotomy surgical approach for chronic instrumentation in dogs and monkeys providing high-quality electrocardiogram signals","volume":"62","author":"Henriques","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2023.107270_bb0170","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.vascn.2013.05.004","article-title":"Preclinical QT safety assessment: Cross-species comparisons and human translation from an industry consortium","volume":"69","author":"Holzgrefe","year":"2014","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2023.107270_bb0175","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.vascn.2006.05.007","article-title":"Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys","volume":"55","author":"Holzgrefe","year":"2007","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2023.107270_bb0180","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1161\/01.RES.72.1.75","article-title":"Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide","volume":"72","author":"Jurkiewicz","year":"1993","journal-title":"Circulation Research"},{"issue":"4","key":"10.1016\/j.vascn.2023.107270_bb0185","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1542-474X.2006.00120.x","article-title":"Magnitude of error introduced by application of heart rate correction formulas to the canine QT interval","volume":"11","author":"King","year":"2006","journal-title":"Annals of Noninvasive Electrocardiology"},{"key":"10.1016\/j.vascn.2023.107270_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2019.106606","article-title":"Exposure-response analysis of drug-induced QT interval prolongation in telemetered monkeys for translational prediction to human","volume":"99","author":"Komatsu","year":"2019","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2023.107270_bb0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.vascn.2015.05.008","article-title":"Evaluation of cardiovascular changes in dogs administered three positive controls using jacketed external telemetry-blood pressure (JET-BP)","volume":"75","author":"Kremer","year":"2015","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2023.107270_bb0200","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.vascn.2010.10.001","article-title":"Characterization of cardiac repolarization in the Gottingen minipig","volume":"63","author":"Laursen","year":"2011","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"7","key":"10.1016\/j.vascn.2023.107270_bb0205","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/bjp.2008.265","article-title":"The effect of changes in core body temperature on the QT interval in beagle dogs: A previously ignored phenomenon, with a method for correction","volume":"154","author":"van der Linde","year":"2008","journal-title":"British Journal of Pharmacology"},{"issue":"11","key":"10.1016\/j.vascn.2023.107270_bb0210","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/etc.4847","article-title":"The minimum detectable difference (MDD) concept for establishing trust in nonsignificant results: A critical review","volume":"39","author":"Mair","year":"2020","journal-title":"Environmental Toxicology and Chemistry"},{"issue":"1","key":"10.1016\/j.vascn.2023.107270_bb0215","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vascn.2013.04.006","article-title":"Intravenous solid tip ECG lead placement in telemetry implanted dogs: Part 2: High quality telemetry signals yield high sensitivity to drug-induced changes","volume":"68","author":"Mitchell","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2023.107270_bb0220","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1540-8167.1999.tb00673.x","article-title":"The molecular and ionic specificity of antiarrhythmic drug actions","volume":"10","author":"Nattel","year":"1999","journal-title":"Journal of Cardiovascular Electrophysiology"},{"issue":"9","key":"10.1016\/j.vascn.2023.107270_bb0225","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/BF03261967","article-title":"Early investigation of QTc liability: The role of multiple ascending dose (MAD) study","volume":"35","author":"Shah","year":"2012","journal-title":"Drug Safety"},{"issue":"1","key":"10.1016\/j.vascn.2023.107270_bb0230","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.vascn.2010.05.011","article-title":"Cardiovascular safety assessments in the conscious telemetered dog: Utilisation of super-intervals to enhance statistical power","volume":"62","author":"Sivarajah","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"27","key":"10.1016\/j.vascn.2023.107270_bb0235","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1002\/sim.4073","article-title":"The analysis of very small samples of repeated measurements I: An adjusted sandwich estimator","volume":"29","author":"Skene","year":"2010","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1016\/j.vascn.2023.107270_bb0240","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cpt.2137","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and Proarrhythmia risk (ICH E14\/S7B updates)","volume":"109","author":"Strauss","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1016\/j.vascn.2023.107270_bb0245","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.vascn.2008.02.001","article-title":"Evaluation of cardiovascular and ECG parameters in normal, freely moving Gottingen Minipig","volume":"57","author":"Stubhan","year":"2008","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"4","key":"10.1016\/j.vascn.2023.107270_bb0250","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1378\/chest.125.4.1561","article-title":"The clinical value of the ECG in noncardiac conditions","volume":"125","author":"Van Mieghem","year":"2004","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.vascn.2023.107270_bb0255","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2029","article-title":"Time for a fully integrated nonclinical-clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective","volume":"109","author":"Vargas","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.vascn.2023.107270_bb0260","doi-asserted-by":"crossref","unstructured":"Vargas, H.M., Rossman, E.I., Wisialowski, T.A., Nichols, J., Pugsley, M.J., Roche, B., & \u2026Leishman, D.J. (2023). Improving the in vivo QTc assay: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute. Journal of Pharmacological and Toxicological Methods. 2023;121:107265. doi:10.1016\/j.vascn.2023.107265.","DOI":"10.1016\/j.vascn.2023.107265"},{"issue":"1","key":"10.1016\/j.vascn.2023.107270_bb0265","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.vascn.2013.04.001","article-title":"Intravenous solid tip lead placement in telemetry implanted dogs. Part 1: Surgical methods, signal quality, and pathological endpoints","volume":"68","author":"Walisser","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2023.107270_bb0270","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1186\/s13063-019-3732-6","article-title":"Correction to: Sample size estimation for randomised controlled trials with repeated assessment of patient-reported outcomes: What correlation between baseline and follow-up outcomes should we assume?","volume":"20","author":"Walters","year":"2019","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.vascn.2023.107270_bb0275","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1186\/s13063-019-3671-2","article-title":"Sample size estimation for randomised controlled trials with repeated assessment of patient-reported outcomes: What correlation between baseline and follow-up outcomes should we assume?","volume":"20","author":"Walters","year":"2019","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.vascn.2023.107270_bb0280","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.vascn.2011.03.002","article-title":"Pharmacokinetic-pharmacodynamic modelling of the effect of moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys","volume":"63","author":"Watson","year":"2011","journal-title":"Journal of Pharmacological and Toxicological Methods"}],"updated-by":[{"DOI":"10.1016\/j.vascn.2025.108392","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000}}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871923000217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871923000217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:07:50Z","timestamp":1761005270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871923000217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":56,"alternative-id":["S1056871923000217"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2023.107270","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14\/S7B Q&As","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2023.107270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107270"}}